▴ Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells.
▴ Rituximab reduced peripheral B lymphocyte counts by ≈90% within 3 days in patients with relapsed indolent lymphoma. Counts remained depleted for 6 months and recovered by months 9 to 12 after 4 doses of rituximab 375 mg/m2 once weekly.
▴ Clinical response rates were 46 and 48% in 2 non-comparative trials in patients with relapsed indolent lymphoma. The rate of response to rituximab appeared to be markedly higher in patients with follicular lymphoma than in those with small lym-phocytic disease (56 or 60% versus 13 or 15%).
▴ 85 to 94% of patients reported adverse events during clinical trials of rituximab; 90% of events were mild or moderate. The most common adverse event, a transient set of flu-like symptoms during the first infusion in approximately 50 to 87% of patients, generally resolved completely in <3 hours. Diphenhydramine and/or paracetamol was administered to some patients.
▴ In 10% of patients, the flu-like symptoms during the first infusion were accompanied by broncho-spasm and/or hypotension or severe cytokine release syndrome. Patients were generally able to complete treatment after these symptoms resolved.
KeywordsAdis International Limited Clinical Response Rate Indolent Lymphoma Hematologic Malignancy Patient Relapse Indolent Lymphoma
Unable to display preview. Download preview PDF.
- 1.Nadler LM. The malignant lymphomas. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill Inc., 1991: 1599–612Google Scholar
- 4.Fisher RI, Oken MM. Clinical practice guidelines: non-Hodgkin’s lymphomas. Cleve Clin J Med 1995; 62 Suppl. 1: 6–42Google Scholar
- 7.Urba WJ, Longo DL. Lymphocytic lymphomas: clinical course and management. In: Moossa AR, Schimpff SC, Robson MC, editors. Comprehensive textbook of oncology. 2nd ed. v. 2. Baltimore: Williams and Wilkins, 1991: 1277–95Google Scholar
- 14.Mathas S, Kommert K, Dörken B, et al. Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation [abstract]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 405aGoogle Scholar
- 17.Gianni AM, Magni M, Di Nicola M, et al. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with rituximab and high-dose chemotherapy [abstract no. 481]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 119aGoogle Scholar
- 22.Gupta RK, Summers KE, Lister TA. PCR analysis for the t(14;18) translocation in patients with recurrent follicular lymphoma following immunotherapy with rituximab (IDEC-C2B8) [abstract no. 974]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 239aGoogle Scholar
- 24.Piro L, White CA, Grillo-Lopez AJ, et al. Rituxan™(rituximab, IDEC-C2B8): interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin’s lymphoma [abstract no. 2272]. Blood 1997 Nov 15; 90 Suppl. 1, Part 1: 510aGoogle Scholar
- 25.Davis T, Levy R, White CA, et al. Rituximab: phase II (PII.) retreatment (ReRx) study in patients (pts) with low-grade or follicular (LG/F) NHL [abstract no. 1710]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 414aGoogle Scholar
- 26.Foran JM, Rohatiner AZS, Cunningham D, et al. Immunotherapy of recurrent follicular lymphoma (FL) with rituximab (IDEC-C2B8): preliminary results of an ongoing UK multi-centre trial [abstract no. P-0969]. Br J Haematol 1998 Jul; 102(1): 243Google Scholar
- 27.Foran JM, Rohatiner AZS, Cunningham D, et al. Immunotherapy of mantle cell lymphoma (MCL), lymphoplasmacytoid lymphoma (LPC) and Waidenstrom’s macroglobulinemia (WM), and small lymphocytic lymphoma (SLL) with rituximab (IDEC-C2B8): preliminary results of an ongoing international multicentre trial [abstract no. O-0586]. Br J Haematol 1998 Jul; 102(1): 149Google Scholar
- 28.Piro L, White CA, Grillo-López AJ, et al. Rituximab in patients (pts) with relapsed low-grade or follicular non-Hodgkin’s lymphoma (LG/F NHL): response rate and duration with a weekly times 8 dosing regimen [abstract no. 49]. Proc Am Soc Clin Oncol 1999; 18: 14aGoogle Scholar
- 29.Janakiraman N, McLaughlin P, White CA, et al. Rituximab: correlation between effector cells and clinical activity in NHL [abstract no. 1384]. Blood 1998 Nov 15; 92 Suppl. 1, Pt 1: 337aGoogle Scholar
- 30.McLaughlin P, Grillo-Lopez AJ, Maloney DG, et al. Efficacy controls and long term follow-up of patients (pts) treated with rituximab for relapsed or refractory, low-grade or follicular (R-LB/F) NHL [abstract no. 1712]. Blood 1998 Nov 15; 92 Suppl. l, Part 1: 414aGoogle Scholar
- 31.Maloney DG, Davis T, Levy R. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. Reply [letter]. J Clin Oncol 1998 Apr; 16: 1636–7Google Scholar
- 33.Davis T, Levy R, White CA, et al. Retreatments with RITUXAN (rituximab, Idec-C2B8) have significant efficacy, do not cause hama, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin’s lymphoma (NHL) [abstract no. 2269]. Blood 1997 Nov 15; 90 Suppl. 1, Part 1: 509Google Scholar
- 34.Hainsworth JD, Burris H, Scullin DC, et al. Rituximab induction and maintenance therapy in patients (pts) with previously untreated low-grade non-Hodgkin’s lymphoma (NHL): preliminary results of Minnie Pear Cancer Research Network phase II trial [abstract no. 105]. Proc Am Soc Clin Oncol 1999; 18: 29Google Scholar
- 36.Czuczman M, Grillo-Lopez AJ, White CA, et al. Rituximab/ CHOP chemoimmunotherapy in patients (pts) with low grade lymphoma (LG/F NHL): progression free survival (FPS) after three years (median) follow up. 1999, Roche Pharmaceuticals, data on fileGoogle Scholar
- 37.Davis T, Maloney D, White CA, et al. Combination immunotherapy of low grade or follicular non-Hodgkins lymphoma with rituximab and alpha interferon: interim analysis [abstract no. 39]. Proc Am Soc Clin Oncol 1998 May; 17: 11aGoogle Scholar
- 38.Coiffier B. Rituximab in diffuse large B cell and mantle cell lymphomas [abstract no. 020]. Ann Oncol 1998; 9 Suppl. 3: 27Google Scholar
- 39.Tsai DE, Moore HCF, Porter DL, et al. Progressive intermediate grade non-Hodgkin’s lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCT) has a high response rate to rituximab [abstract no. 1713]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 415aGoogle Scholar
- 41.Byrd JC, White CA, Link B, et al. Rituximab therapy in previously treated Waldenstrom’s macroglobulinemia: preliminary evidence of activity [abstract no. 433]. Blood 1998 Nov 15; 92 Suppl. 1, Pt 1: 106aGoogle Scholar
- 42.Link BK, Grossbard ML, Fisher RI, et al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade NHL [abstract no. 7]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 3aGoogle Scholar
- 43.NewsEdge Corporation. Roche’s rituximab European warnings strengthened following eight cases of severe cytokine release syndrome; Idec/Genentech discussing Rituxan labeling revisions with FDA. Health News Daily [online], 1 Dec 1998, Media release, downloaded 3 Dec 1998Google Scholar
- 44.Janeway CA, Travers P. Immunobiology: the immune system in health and disease. London: Current Biology Ltd, 1994Google Scholar
- 45.IDEC Pharmaceuticals Corporation, Genentech Inc. Rituxan (rituximab) prescribing information. Revised 1998 SepGoogle Scholar
- 46.Anonymous. Fatal ADRs with Roche’s MabThera. Scrip 1998 Dec 4; 2393: 17Google Scholar
- 47.Hoffmann-La Roche AG. MABTHERA (Rituximab) prescribing information. Revised 27 Nov 1998Google Scholar
- 48.Byrd JC, Waselenko JK, Maneatis TA, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid tumor lysis [abstract no. 432]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 106aGoogle Scholar
- 50.Winkler U, Jensen M, Manzke O, et al. Severe side effects in patients with B-cell chromic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab [abstract no. 4228]. Blood 1998 Nov 15; 92 Suppl. 1, Part 2: 285bGoogle Scholar